



FTW
\$

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of
LOHRAY et al.

Confirmation No. 1052

Atty. Ref.: 4062-127

Appln. No. 10/509,894

T.C. / Art Unit: 1626

Filed: July 6, 2005

Examiner: J.M. Nolan

FOR: HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION,
PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN
MEDICINE (as amended)

* * *

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

August 9, 2007

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Further to the Information Disclosure Statement (IDS) of October 1, 2004,
attached is Form PTO-1449 listing U.S. patent documents and the enclosed non-U.S.
patent documents.

The fee required under 37 CFR § 1.97(c) is filed herewith. But should that fee be
missing or inadequate, please charge the deficiency to our Deposit Account No. 14-
1140 under Order No. 4062-127.

This IDS is intended to be in full compliance with the rules, but should the
Examiner find any part of its required content to have been omitted, prompt notice to
that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to
enable Applicants to comply fully. In particular, if any of the listed documents are
missing or incomplete, please contact the undersigned who will provide another copy.

As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this
information and the listed references are prior art merely because they have been

08/10/2007 JADD01 00000060 10509894

01 FC:1006

100.00 0P
1237128

LOHRAY et al. – Appln. No. 10/509,894

submitted for consideration. Furthermore, no representation is being made that a search has been conducted or that this statement encompasses all possible material information.

Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per M.P.E.P. § 609, are earnestly solicited. The Examiner is invited to contact the undersigned if any further information is needed.

Respectfully submitted,

NIXON & VANDERHYE P.C.


By: _____

Gary R. Tanigawa
Reg. No. 43,180

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE
CITATION

(Use several sheets if necessary)



Atty. Docket No.

Serial No.

4062-127

10/509,894

Applicant

LOHRAY et al.

Filing Date

T.C./A.U.

July 6, 2005

1626

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,633,272	05/1997	Talley			
	5,859,257	01/1999	Talley			
	5,985,902	11/1999	Talley			
	6,020,343	02/2000	Belley et al.			
	6,673,818 B2	01/2004	Brown et al.			16-Apr-2002
	6,699,884 B2	03/2004	Brown et al.			12-Dec-2002
	2003/0032657 A1	02/2003	Brown et al.			16-Apr-2002
	2003/0114456 A1	06/2003	Rosales et al.			25-Oct-2002
	2003/0149078 A1	08/2003	Brown et al.			12-Dec-2002

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
01/83475 A1	11/2001	WO			
1251126 A2	10/2002	EP			
1251126 A3	10/2002	EP			
03/087062 A3	11/2003	WO			

OTHER DOCUMENTS (including Author, Title, Pertinent pages, Date, etc.)

	PUIG et al. "Synthesis and biological evaluation of 3,4-diaryloxazolones: A new class of orally active cyclooxygenase-2 inhibitors" Journal of Medicinal Chemistry, vol. 43, no. 2, pp. 214-223 (2000).
	PENNING et al. "Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)" Journal of Medicinal Chemistry, vol. 40, no. 9, pp. 1347-1365 (1997).
	SHIN et al. "2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors" Bioorganic & Medicinal Chemistry Letters, vol. 11, no. 2, pp. 165-168 (2001).
	FRIESEN et al. "2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors" Bioorganic & Medicinal Chemistry Letters, vol. 8, no. 19, pp. 2777-2782 (1998).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.